

# Greece

## Tuberculosis profile

Population 2015

11 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.092 (0.086–0.098)	0.84 (0.79–0.89)
Mortality (HIV+TB only)	<0.01 (0–0.013)	0.02 (0–0.12)
Incidence (includes HIV+TB)	0.49 (0.42–0.56)	4.5 (3.8–5.1)
Incidence (HIV+TB only)	0.02 (0.015–0.025)	0.18 (0.14–0.22)
Incidence (MDR/RR-TB)**	0.011 (0–0.028)	0.1 (0–0.26)

Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.021 (0.017–0.026)	0.13 (0.075–0.19)	0.15 (0.092–0.21)
Males	<0.01 (<0.01–<0.01)	0.33 (0.26–0.4)	0.34 (0.26–0.41)
Total	0.027 (0.019–0.034)	0.46 (0.42–0.5)	0.49 (0.42–0.56)

TB case notifications, 2015

Total cases notified	482
Total new and relapse	438
- % tested with rapid diagnostics at time of diagnosis	43%
- % with known HIV status	
- % pulmonary	88%
- % bacteriologically confirmed among pulmonary	85%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	90% (78–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.19 (0.16–0.23)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			10 (0–23)
Estimated % of TB cases with MDR/RR-TB	1.5% (0.04–8)	9.1% (0.23–41)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014		
Previously treated cases registered in 2014		
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)
------------------------------------


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive — MDR/RR-TB — XDR-TB